AI Stock Analysis - Clearside Biomedical (CLSD)
Analysis generated September 11, 2025.
Clearside Biomedical, rooted in the biopharmaceutical industry, focuses on developing innovative drug therapies to treat serious eye diseases. The company leverages its proprietary SCS Microinjector platform to enhance the delivery of therapeutics to the back of the eye. This focus on specialized delivery mechanisms differentiates Clearside Biomedical from other companies in the biopharma space, positioning it uniquely for potential advancements in ocular treatments.
Stock Alerts - Clearside Biomedical (CLSD)
 |
Clearside Biomedical | November 28 Price is down by -18.1% in the last 24h. |
|
Clearside Biomedical | November 26 Price is down by -6.6% in the last 24h. |
|
Clearside Biomedical | November 25 Price is down by -18.9% in the last 24h. |
|
Clearside Biomedical | November 24 Price is down by -69.8% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Clearside Biomedical
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,032 | Sign up | Sign up | Sign up |
| X Followers | 268 | Sign up | Sign up | Sign up |
| X Mentions | 1 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 31 | Sign up | Sign up | Sign up |
About Clearside Biomedical
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
| Price | $0.41 |
| Target Price | Sign up |
| Volume | 2,770,000 |
| Market Cap | $2.1M |
| Year Range | $0.41 - $13.27 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
$15.5 Bn Next Generation Drug Conjugates Market Trends and Global Forecasts, 2035January 19 - GlobeNewswire |
|
Uveitis Global Clinical Trials Review Report 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point StatusJanuary 15 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 200,000 | 0 | 200,000 | -6M | -3.3M | -1.140 |
| Q2 '25 | 490,000 | 84,000 | 410,000 | -4.5M | -1.6M | -0.100 |
| Q1 '25 | 2.3M | 250,000 | 2.1M | -8.2M | -4.8M | -0.110 |
| Q4 '24 | 310,000 | 150,000 | 160,000 | -7.3M | -4.6M | -0.100 |
| Q3 '24 | 1M | 0 | 1M | -7.7M | -5.2M | -0.100 |
Insider Transactions View All
| Thorp Clay filed to buy 176,141 shares at $0.9. February 24 '25 |
| Chong Ngai Hang Victor filed to buy 100,000 shares at $1. November 4 '24 |
| Chong Ngai Hang Victor filed to buy 63,500 shares at $1.1. June 24 '24 |
| YERXA BENJAMIN R filed to buy 17,957 shares at $1.3. May 15 '24 |
| Gibney Anthony S filed to buy 100,000 shares at $1.3. April 19 '24 |
Similar companies
Read more about Clearside Biomedical (CLSD) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Clearside Biomedical
The Market Cap of Clearside Biomedical is $2.1M.
Currently, the price of one share of Clearside Biomedical stock is $0.41.
The CLSD stock price chart above provides a comprehensive visual representation of Clearside Biomedical's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Clearside Biomedical shares. Our platform offers an up-to-date CLSD stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Clearside Biomedical (CLSD) does not offer dividends to its shareholders. Investors interested in Clearside Biomedical should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Clearside Biomedical are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
